Repository emulsion therapy for mountain cedar pollinosis: A double-blind study

Miller, Floyd F.; Smith, Robert E.; Lawson, William J.

doi:10.1016/0021-8707(64)90043-7

Cited by 13 publications

(5 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Few studies, not always conclusive ones, have been devoted to Juniperus pollen injection immunotherapy [30,31,32,33,34,35] and, to our knowledge, the present study is the first to analyze SLIT for cypress allergy. The effect of treatment on the clinical features was not significant, but, despite pollen seasons of normal intensity, the patients’ symptoms generally remained present but were not too irritating.…”

Section: Discussionmentioning

confidence: 99%

Safety and Efficacy of Juniperus ashei Sublingual-Swallow Ultra-Rush Pollen Immunotherapy in Cypress Rhinoconjunctivitis

Vervloët

Birnbaum

Laurent³

et al. 2006

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: The safety and efficacy of high-dose sublingual-swallow immunotherapy (SLIT) has been established in pollen rhinoconjunctivitis. This treatment has now been evaluated using an ultra-rush incremental dose regimen with a Juniperus ashei allergen extract in patients allergic to Cupressus sempervirens and Cupressus arizonica. Methods: Patients received either placebo or SLIT. Evaluation of safety was based on the frequency of adverse events during the incremental dose period (half a day) and during maintenance therapy (4 months). Evaluation of efficacy was based on symptom and medication scores at the pollen peak. Results: Seventy of the 76 patients included completed the study. There were no drop-outs during the rush procedure. One patient in the active group dropped out during the maintenance therapy due to adverse events: gastric pain and vomiting. There was also 1 drop-out in the placebo group due to pregnancy. Adverse events were infrequent, local and mild. Symptom scores for rhinitis and conjunctivitis were not statistically different between groups, but there was a marked and significant (p < 0.03) decrease of the medication score (about 50%) and nasal steroid consumption (about 75%) in the active treatment group. An increase from baseline of serum IgE and IgG4 J. ashei-specific antibodies was only observed in actively treated patients (p < 0.04 and p < 0.01, respectively). Conclusions: The tolerability and safety of high-dose ultra-rush SLIT were comparable to those reported in previous SLIT studies. SLIT with J. ashei extract, due to its high Jun a 1 content, significantly reduced nasal steroid consumption in patients allergic to European cypress.

show abstract

Section: Discussionmentioning

confidence: 99%

Safety and Efficacy of Juniperus ashei Sublingual-Swallow Ultra-Rush Pollen Immunotherapy in Cypress Rhinoconjunctivitis

Vervloët

Birnbaum

Laurent³

et al. 2006

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…In a study conducted by Miller et al [9] in Texas, subcutaneous injection of J. ashei was compared to placebo in two groups of 17 patients. This 3-month treatment did not induce any statistically significant difference between groups in terms of rhinitis and sometimes asthma symptoms.…”

Section: Discussionmentioning

confidence: 99%

Immunotherapy with an Aluminum Hydroxide-Adsorbed Juniperus ashei Foreign Pollen Extract in Seasonal Indigenous Cypress Pollen Rhinoconjunctivitis

Charpin¹,

Gouitaa²,

Dron‐Gonzalvez³

et al. 2007

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background:The efficacy of standardized Juniperus ashei extract was assessed in patients with allergic rhinoconjunctivitis due to European cypress pollens. Methods:Forty adults with European cypress-allergic rhinoconjunctivitis were randomized to receive immunotherapy or a matched placebo. Specific immunotherapy was performed with a standardized, aluminum hydroxide-adsorbed J. ashei extract with a potency of 100 IR (arbitrary index of reactivity) containing 54 µg of Jun a 1/ml (Alustal, Stallergenes, France). Subcutaneous injections started in October 2000. The maintenance dose was 0.30 ml of the 100-IR concentration per month. Rhinitis and conjunctivitis symptoms were rated according to a 4-point score. Results: Seventeen patients from the treated group and 15 patients from the placebo group completed year 2001; 14 in each group completed year 2002. A statistically significant improvement (41%, p < 0.02) in the conjunctivitis symptom score was observed in actively treated patients compared to the placebo group at the peak of the 2001 pollen season. Improvement in rhinitis (17%) was not significant. This significant improvement was greater at the peak of the 2002 pollen season (63%, p < 0.01). Conclusions: This study therefore indirectly validates the concept of treatment by major allergen because J. ashei is absent from the region in which this study was conducted.

show abstract

“…At mid‐range, select and commercialize low‐ or nonallergenic trees for planting in population centres. The question of how much would such an elimination programme change the airborne pollen load needs further investigation. At the patient level, specific immunotherapy has been tested using different pollen extracts and different routes (Table 4) (55–57, 59–65). Specific immunotherapy seems to provide variable results.…”

Section: Preventive Treatmentsmentioning

confidence: 99%

“…At the patient level, specific immunotherapy has been tested using different pollen extracts and different routes (Table 4) (55–57, 59–65). Specific immunotherapy seems to provide variable results.…”

Section: Preventive Treatmentsmentioning

confidence: 99%

Allergy to cypress pollen

Charpin

Calleja²,

Lahoz

et al. 2005

Allergy

117

View full text Add to dashboard Cite

Although Cupressus sempervirens has been spread over southern Europe since antiquity, cypress pollen allergy has not been reported until 1945 (1). In France, the very first case reports were published in 1962 (2). Since then, the prevalence of cypress pollinosis seems to demonstrate an upward trend, concomitantly with the increased use of cypress trees as ornamental plants, as wind breaks and as hedges. Hyposensitization, using improved pollen extracts, is increasingly prescribed. Besides, prevention measures begin to be implemented. Such measures include avoidance of planting new cypress trees, especially near human populations’ centres, trimming of cypress hedges before the pollination season and agronomical research for hypoallergenic trees. Altogether, such new developments in cypress allergy deserve an update review.

show abstract

Repository emulsion therapy for mountain cedar pollinosis: A double-blind study

Cited by 13 publications

References 4 publications

Safety and Efficacy of <i>Juniperus ashei</i> Sublingual-Swallow Ultra-Rush Pollen Immunotherapy in Cypress Rhinoconjunctivitis

Safety and Efficacy of <i>Juniperus ashei</i> Sublingual-Swallow Ultra-Rush Pollen Immunotherapy in Cypress Rhinoconjunctivitis

Immunotherapy with an Aluminum Hydroxide-Adsorbed <i>Juniperus ashei</i> Foreign Pollen Extract in Seasonal Indigenous Cypress Pollen Rhinoconjunctivitis

Allergy to cypress pollen

Contact Info

Product

Resources

About